Compare General Dynamics Corporation (GD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs BIO-TECHNE Corp — how do they compare? General Dynamics Corporation trades at $365.81 (market cap $98.88B), while BIO-TECHNE Corp trades at $71.66 (market cap $11.14B). The key difference: General Dynamics Corporation is far larger — about 8.9× BIO-TECHNE Corp's market cap, and General Dynamics Corporation pays the higher dividend (1.74%). Which is the better fit depends on your goals.
| GD | TECH | |
|---|---|---|
Market Cap | $98.88B | $11.14B |
Sector | Industrials | Health |
52-Week High | $376.88 | $71.48 |
52-Week Low | $297.05 | $43.31 |
Enterprise Value | $105.06B | $11.22B |
Dividend Yield | 1.74% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $369.5, down 0.88% on the day, with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $4.10 surpassing the $3.67 expectation. Revenue growth is robust, reaching $52.55B in 2025, while net income margin improved to 8.07%. The stock is supported by a substantial $130.8 billion backlog and a consistent dividend, with the next payment of $1.59 scheduled for August 7, 2026.
The outlook for GD is positive, driven by strong defense spending tailwinds, naval contract dominance, and consistent earnings beats. Investment opportunities include exposure to growing submarine and C5ISR markets. Key risks involve execution on massive backlogs, potential defense budget volatility, and valuation metrics (P/E of 23.01) that are above some industry peers, requiring sustained growth to justify.
Bio-Techne Corporation (TECH) trades at $71.66, near its all-time high, following Merck KGaA's announced $73 per share cash acquisition offer, representing a 24% premium. The stock shows a bullish technical trend, while fundamental metrics reveal a high valuation with a P/E of 102.12 and a net income margin of 9.05%. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. Analyst consensus is evenly split between Buy and Hold, with a $67.75 price target below the current offer price.
The investment outlook is dominated by the pending acquisition by Merck KGaA. The primary opportunity is the realization of the $73 per share offer, providing a clear exit near current levels. Key risks include potential deal completion delays, regulatory scrutiny, and shareholder litigation questioning the fairness of the price. Should the deal fall through, the stock faces significant downside pressure given its stretched valuation and recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
